AR073459A1 - Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso - Google Patents
Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de usoInfo
- Publication number
- AR073459A1 AR073459A1 ARP090102733A ARP090102733A AR073459A1 AR 073459 A1 AR073459 A1 AR 073459A1 AR P090102733 A ARP090102733 A AR P090102733A AR P090102733 A ARP090102733 A AR P090102733A AR 073459 A1 AR073459 A1 AR 073459A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- variable domain
- monovalent
- methods
- single variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Se relaciona con un dominio de polipéptido monovalente que se une de manera específica a CD28, al igual que con un antagonista de CD28, donde el antagonista comprende un dominio de polipéptido monovalente que se une de manera especifica a CD28. Dominios de polipéptidos monovalentes que comprenden un dominio variable simple de anticuerpo que se une de manera monovalente a CD28. Un dominio variable simple de anticuerpo que es monovalente para la union de CD28 puede inhibir la actividad de CD28. En un aspecto, un dominio variable simple de anticuerpo anti-CD28 monovalente comprende o consiste en un dominio variable simple de anticuerpo que se une de manera específica a CD28 y antagonista su actividad, en un aspecto, sin agonizar de manera sustancial la actividad de CD28. En otro aspecto, el dominio variable simple de anticuerpo anti-CD28 monovalente es un dominio variable simple de anticuerpo humano. Además contempla métodos para la antagonizacion de las interacciones de CD80 y/o CD86 con CD28 en un individuo, y métodos para el tratamiento de enfermedades o trastornos que involucran interacciones de CD80 y/o CD86 con CD28; donde los métodos comprenden la administracion de un dominio variable simple de anticuerpo anti-CD28 monovalente al individuo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US755308P | 2008-07-18 | 2008-07-18 | |
| US17603608A | 2008-07-18 | 2008-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073459A1 true AR073459A1 (es) | 2010-11-10 |
Family
ID=41316544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102733A AR073459A1 (es) | 2008-07-18 | 2009-07-17 | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2315778A2 (es) |
| JP (1) | JP2012507260A (es) |
| AR (1) | AR073459A1 (es) |
| WO (1) | WO2010007376A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| ES2857226T3 (es) | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CR20180279A (es) | 2015-11-18 | 2018-08-24 | Merck Sharp & Dohme | Enlazadores de ctla4 |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| EP3806848A2 (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| CN117534761A (zh) * | 2023-11-20 | 2024-02-09 | 上海百英生物科技股份有限公司 | 一种抗cd28纳米抗体及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| AU2007331672A1 (en) * | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
-
2009
- 2009-07-17 WO PCT/GB2009/001762 patent/WO2010007376A2/en active Application Filing
- 2009-07-17 AR ARP090102733A patent/AR073459A1/es unknown
- 2009-07-17 EP EP09784717A patent/EP2315778A2/en not_active Withdrawn
- 2009-07-17 JP JP2011517992A patent/JP2012507260A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010007376A2 (en) | 2010-01-21 |
| WO2010007376A3 (en) | 2010-05-27 |
| JP2012507260A (ja) | 2012-03-29 |
| EP2315778A2 (en) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073459A1 (es) | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso | |
| CO6341641A2 (es) | Composiciones monovalentes para union a cd28 y metodos de uso | |
| BR112012023010A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37 | |
| BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
| EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
| EP2331136A4 (en) | FRIZZLED-BINDING SUBSTANCES AND ITS USES | |
| EA201370066A1 (ru) | Модуляторы эстрогеновых рецепторов и их применение | |
| AR077333A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana | |
| EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| MY159679A (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BRPI1009381B8 (pt) | compostos, composição farmacêutica e uso de compostos e de composição farmacêutica | |
| BR112012020273A2 (pt) | Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
| BR112014007426A2 (pt) | anticorpos contra tl 1a e seus usos | |
| UY31622A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2 | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112012018766A2 (pt) | métodos de tratamento de doenças autoimunes com antagonistas de dll4. | |
| EA201390813A1 (ru) | Антитела и их применение | |
| ECSP099296A (es) | Inmuno-reguladores, preparaciones y composiciones que incluyen los inmuno-reguladores, pruebas para evaluar la actividad de los inmuno-reguladores y preparaciones y composiciones que incluyen los mismos y métodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |